Drug companies are starting to tackle antimicrobial resistance but could do more, report showsBMJ 2018; 360 doi: https://doi.org/10.1136/bmj.k269 (Published 23 January 2018) Cite this as: BMJ 2018;360:k269
- Anne Gulland
Just two of 28 new antibiotics in development have adequate stewardship and access provisions in place, a review of the drug industry’s progress on tackling antimicrobial resistance (AMR) has found.1
The antimicrobial resistance benchmark review, conducted by the Access to Medicine Foundation, looks at the 30 most active players in antimicrobial development. The benchmark includes drug multinationals, biotechnology companies, and manufacturers of generic medicine. It ranks companies on a range of indicators, including research and development; manufacturing and production, which includes measures on environmental protection; and access and stewardship (encouraging appropriate use of the drugs).
The report found that drug companies are taking steps to combat …